Clinical Phase II/III Trial of Ustekinumab to Treat Type 1 Diabetes (UST1D2)

Plain-language summary

This study is evaluating the drug Ustekinumab for newly diagnosed type 1 diabetes, compared with placebo. People aged 18 to 35 within 100 days of diagnosis who still have functioning beta cells are eligible. The study is being carried out in Phase 2/Phase 3; it is currently not recruiting but is ongoing (active, not recruiting).

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

PHASE2/PHASE3

Status

Active, not recruiting

Sponsor

University of British Columbia

Intervention

Ustekinumab, Placebo

Start date

1/4/2021

Estimated completion

11/1/2026

Countries

Canada

Related genes

Locations

• Toronto, Canada
• Vancouver, Canada

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1. A diagnosis of type 1 diabetes mellitus in accordance with the ADA/CDA criteria.
2. An interval of ≤100 days between the diagnosis and the first dose of the study drug.
3. Ability to provide documented informed consent.
4. Male or female, aged 18-35 years inclusive, at the time of the anticipated first dose of the study drug.
5. Evidence of residual functioning β cells. This will be assessed by a C-peptide level over 0.2nmol/L in the MMTT test.
6. Positive for at least one diabetes-related autoantibody.
7. Willing to record all insulin taken and blood glucose levels that are required for monitoring during the study, including reporting any hypoglycaemic events.

Exclusion Criteria:

1. No condition that, in the investigators' judgment, is likely to cause the subject to not be able to understand information in order to provide informed consent.
2. History of malignancy.
3. No significant and/or active disease in any body system that is likely to increase the risk to the subject or interfere with the subject's participation in the study.
4. No significant systemic infection during the 6 weeks before the first dose of the study drug.
5. No history of current or past active tuberculosis infection and no latent tuberculosis as per CDC guidelines.
6. Have used any other investigational drug within the 3 months prior to the first dose and/or intend on using any investigational drug for the duration of the study.
7. Prior or current treatment that is known to cause a significant, ongoing change in the course of T1D or immunological status.
8. Current or prior (within 30 days prior to first study drug dose) use of medications known to influence glucose tolerance.
9. No significant abnormal laboratory values during the screening period, other than those due to T1D.
10. Not pregnant, breastfeeding or planning to become pregnant during the 60 days after the last dose of the study drug.
11. Have not received any live vaccines within 30 days prior to the first study drug dose and are not expected to need to receive a vaccine during the study.
12. No prior allergic reaction, including anaphylaxis, to any component of the study drug product.
13. No prior allergic reaction, including anaphylaxis, to any human, humanized, chimeric or rodent antibody treatment.
14. Have not undergone any major surgery within the 30 day period prior to the first drug dose and not anticipating requiring surgery during the study period.
15. Negative results for Hepatitis B surface antigen and for antibodies to Hepatitis B core antigen, or evidence of Hepatitis B surface antibody \> 10 IU, and negative for Hepatitis C. Negative results for HIV and not considered by the investigator to be at high risk for HIV infection.